多发性骨髓瘤抗原表达的预后价值:一项PETHEMA/GEM研究,纳入四项连续临床试验的1265例患者
该研究纳入GEM2000、GEM2005MENOS65、GEM2005MAS65和GEM2010MAS65四项试验的1265例初诊多发性骨髓瘤患者,分析监测微小残留病(MRD)所需抗原的表达预后价值。CD19阳性、CD27阴性、CD38低表达、CD45阳性、CD81阳性、CD117阴性及CD138低表达均预测较差结局;同时CD38低表达、CD81阳性、CD117阴性组合对无进展生存期具有独立预后价值(HR:1.69;P=0.002),且在MRD阳性患者中保留预后价值。
要点
- CD19阳性、CD27阴性、CD38低表达、CD45阳性、CD81阳性、CD117阴性及CD138低表达预测较差结局。
- 同时CD38低表达、CD81阳性、CD117阴性组合对无进展生存期有独立预后价值(HR:1.69;P=0.002)。
- 该表型特征在MRD阳性患者中保留预后价值;除CD81外,监测MRD所需抗原从诊断到MRD阶段大多稳定。
核心结论
- 肿瘤细胞的表型特征提供额外预后信息,可用于进一步预测MRD阳性患者的复发风险。
研究设计与样本
- 研究纳入GEM2000、GEM2005MENOS65、GEM2005MAS65和GEM2010MAS65四项连续临床试验的1265例初诊多发性骨髓瘤患者,分析监测MRD所需抗原表达的预后价值。
主要发现
- CD19阳性、CD27阴性、CD38低表达、CD45阳性、CD81阳性、CD117阴性及CD138低表达总体预测较差结局。
- 通过主成分分析,同时CD38低表达、CD81阳性、CD117阴性组合对无进展生存期具有独立预后价值(HR:1.69;P=0.002)。
- 该独特表型特征在MRD阳性患者中保留预后价值。
- 采用二代流式检测疾病全程抗原稳定性,发现监测MRD所需抗原从诊断到MRD阶段大多稳定,但CD81表达从基线至化疗耐药肿瘤细胞逐渐升高(14% vs 28%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Persistence of minimal residual disease (MRD) after treatment for myeloma predicts inferior outcomes, but within MRD-positive patients there is great heterogeneity with both early and very late relapses. Among different MRD techniques, flow cytometry provides additional information about antigen expression on tumor cells, which could potentially contribute to stratify MRD-positive patients. We investigated the prognostic value of those antigens required to monitor MRD in 1265 newly diagnosed patients enrolled in the GEM2000, GEM2005MENOS65, GEM2005MAS65 and GEM2010MAS65 protocols. Overall, CD19pos, CD27neg, CD38lo, CD45pos, CD81pos, CD117neg and CD138lo expression predicted inferior outcomes. Through principal component analysis, we found that simultaneous CD38lowCD81posCD117neg expression emerged as the most powerful combination with independent prognostic value for progression-free survival (HR:1.69; P=0.002). This unique phenotypic profile retained prognostic value among MRD-positive patients. We then used next-generation flow to determine antigen stability throughout the course of the disease, and found that the expression of antigens required to monitor MRD is mostly stable from diagnosis to MRD stages, except for CD81 whose expression progressively increased from baseline to chemoresistant tumor cells (14 vs 28%). Altogether, we showed that the phenotypic profile of tumor cells provides additional prognostic information, and could be used to further predict risk of relapse among MRD-positive patients.
引用
- Arana P, Paiva B, Cedena MT, et al. Prognostic value of antigen expression in multiple myeloma: a PETHEMA/GEM study on 1265 patients enrolled in four consecutive clinical trials. Leukemia. 2017. PMID: 29099494. doi:10.1038/leu.2017.320
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。